IT201900018047A1 - PROCEDURE FOR THE PREPARATION OF A LIQUID TOPICAL COMPOSITION. - Google Patents
PROCEDURE FOR THE PREPARATION OF A LIQUID TOPICAL COMPOSITION. Download PDFInfo
- Publication number
- IT201900018047A1 IT201900018047A1 IT102019000018047A IT201900018047A IT201900018047A1 IT 201900018047 A1 IT201900018047 A1 IT 201900018047A1 IT 102019000018047 A IT102019000018047 A IT 102019000018047A IT 201900018047 A IT201900018047 A IT 201900018047A IT 201900018047 A1 IT201900018047 A1 IT 201900018047A1
- Authority
- IT
- Italy
- Prior art keywords
- ash
- suspension
- liquid
- topical composition
- process according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 37
- 230000000699 topical effect Effects 0.000 title claims description 23
- 239000007788 liquid Substances 0.000 title claims description 16
- 238000000034 method Methods 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 20
- 239000000725 suspension Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 241001070947 Fagus Species 0.000 claims description 5
- 235000010099 Fagus sylvatica Nutrition 0.000 claims description 5
- 239000000919 ceramic Substances 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 241000167854 Bourreria succulenta Species 0.000 claims description 3
- 241001507924 Sorbus alnifolia Species 0.000 claims description 3
- 235000019693 cherries Nutrition 0.000 claims description 3
- 238000000151 deposition Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 229960002882 calcipotriol Drugs 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000126 substance Chemical class 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
PROCEDIMENTO PER LA PREPARAZIONE DI UNA COMPOSIZIONE TOPICA LIQUIDA PROCEDURE FOR THE PREPARATION OF A LIQUID TOPICAL COMPOSITION
DESCRIZIONE DESCRIPTION
Il presente trovato ha come oggetto una composizione liquida per uso topico, un procedimento per la sua preparazione ed il suo uso. Più in particolare, il presente trovato si riferisce a una composizione acquosa per uso topico per il trattamento di malattie quali la psoriasi. The present invention relates to a liquid composition for topical use, a process for its preparation and its use. More particularly, the present invention relates to an aqueous composition for topical use for the treatment of diseases such as psoriasis.
La psoriasi è una malattia infiammatoria cronica della pelle solitamente di carattere cronico e recidivante. Nella sua patogenesi intervengono fattori autoimmunitari, genetici e ambientali. La psoriasi è una patologia di comune riscontro, senza particolari correlazioni con sesso od età. Psoriasis is a chronic inflammatory skin disease usually chronic and relapsing. Autoimmune, genetic and environmental factors intervene in its pathogenesis. Psoriasis is a common pathology, with no particular correlation with sex or age.
Si riconoscono più forme di psoriasi: la psoriasi pustolosa e forme non pustolose tra cui la psoriasi a placche (circa l'80% delle forme di psoriasi), guttata, inversa ed eritrodermica. Multiple forms of psoriasis are recognized: pustular psoriasis and non-pustular forms including plaque psoriasis (about 80% of psoriasis forms), guttate, inverse and erythrodermal.
Nella psoriasi a placche la pelle si accumula rapidamente e si ispessisce nelle zone interessate dalle lesioni conferendo un aspetto squamoso bianco-argenteo. Anche se il disturbo può comparire in qualsiasi zona del corpo, in genere si localizza in corrispondenza di gomiti, ginocchia, cuoio capelluto e parte lombare della schiena, oltre che ai palmi delle mani, alle piante dei piedi ed in regione genitale. La malattia si presenta più frequentemente, ma non esclusivamente, sulle superfici estensorie degli arti. La malattia, ad andamento cronico e ricorrente, è variabile nell'estensione dell'interessamento cutaneo. Si va da soggetti affetti da un numero molto limitato di piccole chiazze fino a soggetti con il corpo quasi completamente coperto da lesioni. In plaque psoriasis, the skin builds up rapidly and thickens in the areas affected by the lesions, giving a silvery-white scaly appearance. Although the disorder can appear in any area of the body, it generally occurs in the elbows, knees, scalp and lumbar part of the back, as well as in the palms of the hands, soles of the feet and in the genital region. The disease occurs most frequently, but not exclusively, on the extensor surfaces of the limbs. The chronic and recurrent disease is variable in the extent of skin involvement. They range from subjects with a very limited number of small patches to subjects with the body almost completely covered by lesions.
Tra le cure disponibili, si segnalano i farmaci per uso topico, cioè applicati direttamente sulla pelle, Among the treatments available, there are drugs for topical use, that is applied directly to the skin,
Una prima tipologia di farmaci per uso topico sono i cosiddetti emollienti e idratanti: si tratta dei rimedi più blandi, utili in monoterapia nei casi più leggeri o in associazione ad altri farmaci per uso topico; l’obiettivo è quello di mantenere la pelle idratata ed eventualmente creare un film protettivo, questo permette di ridurre prurito e desquamazione. A first type of drugs for topical use are the so-called emollients and moisturisers: these are the mildest remedies, useful in monotherapy in the lightest cases or in association with other drugs for topical use; the goal is to keep the skin hydrated and possibly create a protective film, this allows to reduce itching and flaking.
Un'altra tipologia di farmaci utilizzati è costituita di farmaci cortisonici, i quali riducono l’infiammazione della pelle e si dimostrano quasi sempre efficaci nel permettere una regressione dei sintomi; tuttavia, va evitato l’abuso per non incorrere in effetti collaterali anche importanti, questo significa usarli per brevi cicli di terapia e possibilmente su superficie corporea limitata. Another type of drugs used is made up of cortisone drugs, which reduce skin inflammation and are almost always effective in allowing a regression of symptoms; however, abuse must be avoided in order not to incur even important side effects, this means using them for short courses of therapy and possibly on a limited body surface.
Negli ultimi anni sono stati inoltre sviluppati farmaci retinoidi a base di vitamina D3 o analoghi chimici (come per esempio il calcipotriolo, Daivonex® e Psorcutan® per esempio), i quali hanno lo scopo di tenere sotto controllo la sovrapproduzione di cellule della pelle e sono in grado di far regredire i sintomi. In recent years, retinoid drugs based on vitamin D3 or chemical analogues have also been developed (such as calcipotriol, Daivonex® and Psorcutan® for example), which are aimed at controlling the overproduction of skin cells and are able to reverse the symptoms.
Sono spesso usati in alternativa o in associazione ai cortisonici, essendo forse meno efficaci ma sicuramente meglio tollerati. They are often used alternatively or in association with cortisone, being perhaps less effective but certainly better tolerated.
Tuttavia, si è riscontrato come i farmaci impiegati siano in grado di dare benefici sono a breve termine, determinando in molti casi effetti collaterali estremamente fastidiosi. However, it has been found that the drugs used are able to give benefits are short-term, causing in many cases extremely annoying side effects.
Compito precipuo del presente trovato è quello di fornire una composizione acquosa per uso topico che abbia proprietà lenitive e rigeneranti. The aim of the present invention is to provide an aqueous composition for topical use which has soothing and regenerating properties.
Un altro scopo del trovato è quello di fornire un procedimento per la preparazione della composizione acquosa qui descritta che sia economico e di facile realizzazione. Another object of the invention is to provide a process for the preparation of the aqueous composition described here which is economical and easy to produce.
Ancora, la presente invenzione ha come scopo quello di fornire una composizione acquosa per uso topico che sia efficace nel trattamento della psoriasi. Furthermore, the present invention aims to provide an aqueous composition for topical use which is effective in the treatment of psoriasis.
Questo compito, nonché questi ed altri scopi che meglio appariranno in seguito, sono raggiunti da una composizione farmaceutica topica, preferibilmente in forma di pomata, comprendente una miscela costituita da sego bovino, un olio vegetale e litopone. This task, as well as these and other purposes which will appear better below, are achieved by a topical pharmaceutical composition, preferably in the form of an ointment, comprising a mixture consisting of bovine tallow, a vegetable oil and lithopone.
I compiti e gli scopi del presente trovato sono raggiunti anche da un procedimento per la preparazione della composizione acquosa topica qui descritta comprendente i passaggi di: The tasks and purposes of the present invention are also achieved by a process for the preparation of the aqueous topical composition described here, comprising the steps of:
a) miscelare acqua e una cenere scelta nel gruppo costituito da cenere di faggio, cenere di ciliegio, cenere di carpine ed una loro combinazione in un recipiente ottenendo una miscela; a) mixing water and an ash chosen from the group consisting of beech ash, cherry ash, hornbeam ash and their combination in a container to obtain a mixture;
b) riscaldare la detta miscela ottenuta ad una temperatura compresa fra 100 °C e 110 °C e mantenere a detta temperatura per un tempo almeno pari a 15 minuti, ottenendo una sospensione; b) heating the said mixture obtained to a temperature between 100 ° C and 110 ° C and maintaining it at said temperature for at least 15 minutes, obtaining a suspension;
c) far depositare la parte solida di detta sospensione trattata termicamente ; c) depositing the solid part of said thermally treated suspension;
d) rimuovere dall'alto la parte liquida di detta sospensione ottenendo la composizione topica liquida. d) removing the liquid part of said suspension from above obtaining the liquid topical composition.
I compiti e gli scopi del presente trovato sono raggiunti anche dalla composizione topica sopra descritta per la cura della psoriasi. The aims and purposes of the present invention are also achieved by the topical composition described above for the treatment of psoriasis.
Ulteriori caratteristiche e vantaggi del trovato risulteranno maggiormente dalla seguente descrizione dettagliata. Further characteristics and advantages of the invention will become clearer from the following detailed description.
Il procedimento per la preparazione di una composizione topica liquida secondo il trovato comprende i passaggi di: The process for preparing a liquid topical composition according to the invention comprises the steps of:
a) miscelare acqua e una cenere scelta nel gruppo costituito da cenere di faggio, cenere di ciliegio, cenere di carpine ed una loro combinazione in un recipiente ottenendo una miscela; a) mixing water and an ash chosen from the group consisting of beech ash, cherry ash, hornbeam ash and their combination in a container to obtain a mixture;
b) riscaldare la detta miscela ottenuta ad una temperatura compresa fra 100 °C e 110 °C e mantenere a detta temperatura per un tempo almeno pari a 15 minuti, ottenendo una sospensione; b) heating the said mixture obtained to a temperature between 100 ° C and 110 ° C and maintaining it at said temperature for at least 15 minutes, obtaining a suspension;
c) far depositare la parte solida di detta sospensione trattata termicamente; c) depositing the solid part of said thermally treated suspension;
d) rimuovere dall'alto la parte liquida di detta sospensione ottenendo la composizione topica liquida. d) removing the liquid part of said suspension from above obtaining the liquid topical composition.
Opportunamente, la fase di deposito prevede il mantenimento della miscela nel recipiente per almeno 24 ore. Conveniently, the deposit step provides for the mixture to be kept in the container for at least 24 hours.
Vantaggiosamente, la fase di deposito prevede il mantenimento della miscela nel recipiente per un tempo massimo di 48 ore. Advantageously, the deposit step provides for the mixture to be kept in the container for a maximum time of 48 hours.
Opportunamente, la sospensione presenta un rapporto in peso (p/p) tra acqua e cenere compreso tra 7:1 e 3:1, preferibilmente compreso tra 6:1 e 4:1, più preferibilmente di 5:1. Conveniently, the suspension has a weight ratio (w / w) between water and ash comprised between 7: 1 and 3: 1, preferably between 6: 1 and 4: 1, more preferably 5: 1.
In pratica, per ogni 5 kg di acqua si prevede di miscelare circa 1 kg di cenere. In practice, approximately 1 kg of ash is expected to be mixed for every 5 kg of water.
Si è riscontrato essere molto vantaggioso impiegare esclusivamente cenere di faggio. It has been found to be very advantageous to use only beech ash.
Il recipiente utilizzato per effettuare la fase di riscaldare la miscela comprende una superficie interna destinata ad andare a contatto con la sospensione realizzata in ceramica ovvero in vetro. The vessel used to carry out the step of heating the mixture comprises an internal surface intended to come into contact with the suspension made of ceramic or glass.
La fase di rimuovere la parte liquida comprende il riempimento di contenitori in vetro ovvero in ceramica con detta parte liquida. The step of removing the liquid part comprises filling glass or ceramic containers with said liquid part.
Secondo un ulteriore aspetto, il presente trovato riguarda una composizione topica ottenibile secondo il procedimento sopra descritto. According to a further aspect, the present invention relates to a topical composition obtainable according to the process described above.
Ulteriormente, il presente trovato riguarda una composizione acquosa topica ottenuta secondo il procedimento descritto per l'uso nel trattamento della psoriasi. Furthermore, the present invention relates to a topical aqueous composition obtained according to the process described for use in the treatment of psoriasis.
La composizione acquosa per uso topico secondo il trovato è efficace nel trattamento della psoriasi. La composizione del trovato, che può essere applicata anche quotidianamente, esercita un effetto lenitivo e rigenerante sin dalla prima applicazione. The aqueous composition for topical use according to the invention is effective in the treatment of psoriasis. The composition of the invention, which can also be applied daily, has a soothing and regenerating effect from the first application.
Naturalmente, il presente trovato riguarda anche un metodo per il trattamento della psoriasi, mediante applicazione a un paziente della composizione topica secondo una qualsiasi delle forme di realizzazione qui descritte. Naturally, the present invention also relates to a method for treating psoriasis, by applying the topical composition according to any one of the embodiments described here to a patient.
E’ stato trovato che l'applicazione della composizione della presente invenzione determina una sensibile riduzione della psoriasi. It has been found that the application of the composition of the present invention results in a significant reduction in psoriasis.
In particolare, si è proceduto ad applicare la composizione acquosa su soggetti affetti da psoriasi, in corrispondenza della zona della pelle presentante le placche o le pustole, in quantità tale da rendere umida tale zona. In particular, the aqueous composition was applied to subjects suffering from psoriasis, in correspondence with the area of the skin presenting the plaques or pustules, in such quantity as to make this area moist.
I pazienti hanno riscontrato, soprattutto durante le prime applicazioni, un leggero bruciore, seguito tuttavia da una sensazione di sollievo. Patients experienced a slight burning sensation, especially during the first applications, followed, however, by a feeling of relief.
E' stata effettuata l'applicazione su 50 pazienti, 40 dei quali, dopo 20 giorni, presentavano una riduzione di almeno il 50% dell'area interessata dalla psoriasi. The application was carried out on 50 patients, 40 of whom, after 20 days, had a reduction of at least 50% in the area affected by psoriasis.
In 10 pazienti non si è riscontrata una riduzione dell'area di interessamento della psoriasi ma, anche in tutti questi casi, non si è riscontrato un aumento dell'area interessata dalla psoriasi e i pazienti hanno riscontrato un effetto lenitivo. In 10 patients there was no reduction in the area affected by psoriasis but, even in all these cases, there was no increase in the area affected by psoriasis and the patients found a soothing effect.
Dopo i primi 20 giorni di applicazione, si è proceduto a ridurre via via il numero di applicazione della composizione, applicando per i successivi 20 giorni la composizione per due volte al giorno. After the first 20 days of application, the number of applications of the composition was gradually reduced, applying the composition twice a day for the next 20 days.
Al termine del trattamento, 30 dei 50 pazienti iniziali hanno riscontrato sostanzialmente una totale scomparsa delle placche o delle pustole, mentre altri 10 pazienti hanno riscontrato una riduzione dell'area interessata dalla psoriasi di almeno il 70%. At the end of the treatment, 30 of the 50 initial patients found substantially a total disappearance of the plaques or pustules, while the other 10 patients found a reduction of the area affected by psoriasis of at least 70%.
Si è in pratica constatato come la composizione topica liquida secondo il trovato e il procedimento di facile realizzazione per la sua preparazione assolvano pienamente agli scopi del trovato, in quanto mettono a disposizione un efficace trattamento per la psoriasi. In practice it has been found that the liquid topical composition according to the invention and the easy-to-produce process for its preparation fully fulfill the purposes of the invention, since they provide an effective treatment for psoriasis.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102019000018047A IT201900018047A1 (en) | 2019-10-07 | 2019-10-07 | PROCEDURE FOR THE PREPARATION OF A LIQUID TOPICAL COMPOSITION. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102019000018047A IT201900018047A1 (en) | 2019-10-07 | 2019-10-07 | PROCEDURE FOR THE PREPARATION OF A LIQUID TOPICAL COMPOSITION. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT201900018047A1 true IT201900018047A1 (en) | 2021-04-07 |
Family
ID=69743656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102019000018047A IT201900018047A1 (en) | 2019-10-07 | 2019-10-07 | PROCEDURE FOR THE PREPARATION OF A LIQUID TOPICAL COMPOSITION. |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT201900018047A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994011010A2 (en) * | 1992-11-06 | 1994-05-26 | H.E. Stanley Pharmaceuticals, Inc. | Compositions of oak bark extract, related synthetic compositions, and method of using same |
| WO2005000328A1 (en) * | 2003-06-24 | 2005-01-06 | Zanti Gianfranco | Compositions based on plant ash for the treatment of skin diseases |
| DE102007042072A1 (en) * | 2007-09-05 | 2009-03-12 | Gordana Klein | Preparing an agent, for the care and regeneration of hair and scalp, comprises burning beech wood, extracting the ash by reductions, stirring the mixture with boiled water to obtain an alkaline solution and straining the ashes |
-
2019
- 2019-10-07 IT IT102019000018047A patent/IT201900018047A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994011010A2 (en) * | 1992-11-06 | 1994-05-26 | H.E. Stanley Pharmaceuticals, Inc. | Compositions of oak bark extract, related synthetic compositions, and method of using same |
| WO2005000328A1 (en) * | 2003-06-24 | 2005-01-06 | Zanti Gianfranco | Compositions based on plant ash for the treatment of skin diseases |
| DE102007042072A1 (en) * | 2007-09-05 | 2009-03-12 | Gordana Klein | Preparing an agent, for the care and regeneration of hair and scalp, comprises burning beech wood, extracting the ash by reductions, stirring the mixture with boiled water to obtain an alkaline solution and straining the ashes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sánchez-Porras et al. | Pharmacological modulation of spreading depolarizations | |
| MX2011011459A (en) | Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders. | |
| WO2022150732A3 (en) | Chimeric receptor therapy | |
| Holman et al. | Six-year results from the early diabetes intervention trial | |
| IT201900018047A1 (en) | PROCEDURE FOR THE PREPARATION OF A LIQUID TOPICAL COMPOSITION. | |
| AU2021318589A1 (en) | Use of CD44 antibody in preparation of medicine for treating Parkinson's disease | |
| WO2008076824A3 (en) | Therapeutic and diagnostic peptides | |
| WO2021180821A3 (en) | Compositions of il-6/il-6r antibodies and methods of use thereof | |
| WO2018158542A8 (en) | Mesenchymal stem cells obtained from wharton's jelly for the treatment of sepsis | |
| EP3364965A1 (en) | Methods and compositions for treating neurodegenerative diseases | |
| CN103638156B (en) | The vasculitic Chinese medicine preparation for the treatment of blood stasis type | |
| Shi et al. | Inhibitory effect of compound Chuanxiong Kangxian granules on bleomycin-induced pulmonary fibrosis in rats | |
| JP2019514418A5 (en) | ||
| CH693819A5 (en) | Topical formulation for combating cellulite symptoms, containing synergistic combination of coenzyme A, Bupleurum falcarum extract and horse-chestnut extract | |
| JP6034386B2 (en) | Composition for application to the skin and use thereof | |
| JP5980488B2 (en) | Pharmaceutical composition for the treatment of stomatitis | |
| JP6821181B2 (en) | Immunity improving solution, cancer cell healing solution using it | |
| DE502007003627D1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A MASTER SUCH AS AN ALGINIC ACID DERIVATIVE | |
| MA et al. | Effect of Acupoint Thread Embedding on Cognition and PI3K-AKT Signaling Pathway in Epileptic Rats | |
| Xiaoyun et al. | A12570 Angiotensin II Type 1 Receptor mediates the Expression of Collagen Type 1 in Homocysteine stimulated Rat Adventitial Fibroblasts by ERK1/2-STAT3 pathway | |
| Carati et al. | Efficacy of a Dermoxen® lenitiva for pruritus genitalis in a randomized, double blind trial | |
| CN109718267A (en) | A kind of drug and preparation method thereof for treating the fungal infection of the hand | |
| Techner et al. | ADL5945, a potent orally bioavailable peripheral opioid receptor antagonist, improves bowel motility w/a low incidence/severity of GI AEs in a dose-dependent manner: results of 2 Ph 2 trials in opioid-induced constipation pts (45CL242 and 45CL243) | |
| CN1048893C (en) | Zengshengling oil and preparing method thereof | |
| Southern et al. | Uncovering The Mysteries Of S100a4 In Fibrosis: Activation And Localization Of Non-Muscle Myosin Ii Drives Myofibroblast Differentiation |